346 related articles for article (PubMed ID: 28987384)
1. Favorable biodistribution, specific targeting and conditional endosomal escape of RNA nanoparticles in cancer therapy.
Xu C; Haque F; Jasinski DL; Binzel DW; Shu D; Guo P
Cancer Lett; 2018 Feb; 414():57-70. PubMed ID: 28987384
[TBL] [Abstract][Full Text] [Related]
2. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.
Shu D; Li H; Shu Y; Xiong G; Carson WE; Haque F; Xu R; Guo P
ACS Nano; 2015 Oct; 9(10):9731-40. PubMed ID: 26387848
[TBL] [Abstract][Full Text] [Related]
3. Fabrication of 14 different RNA nanoparticles for specific tumor targeting without accumulation in normal organs.
Shu Y; Haque F; Shu D; Li W; Zhu Z; Kotb M; Lyubchenko Y; Guo P
RNA; 2013 Jun; 19(6):767-77. PubMed ID: 23604636
[TBL] [Abstract][Full Text] [Related]
4. Using Planar Phi29 pRNA Three-Way Junction to Control Size and Shape of RNA Nanoparticles for Biodistribution Profiling in Mice.
Haque F; Xu C; Jasinski DL; Li H; Guo P
Methods Mol Biol; 2017; 1632():359-380. PubMed ID: 28730451
[TBL] [Abstract][Full Text] [Related]
5. Hydrophobic Effect from Conjugated Chemicals or Drugs on In Vivo Biodistribution of RNA Nanoparticles.
Jasinski DL; Yin H; Li Z; Guo P
Hum Gene Ther; 2018 Jan; 29(1):77-86. PubMed ID: 28557574
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Size and Shape of RNA Nanoparticles on Biodistribution.
Jasinski DL; Li H; Guo P
Mol Ther; 2018 Mar; 26(3):784-792. PubMed ID: 29402549
[TBL] [Abstract][Full Text] [Related]
7. RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model.
Lee TJ; Haque F; Shu D; Yoo JY; Li H; Yokel RA; Horbinski C; Kim TH; Kim SH; Kwon CH; Nakano I; Kaur B; Guo P; Croce CM
Oncotarget; 2015 Jun; 6(17):14766-76. PubMed ID: 25885522
[TBL] [Abstract][Full Text] [Related]
8. Regression of Gastric Cancer by Systemic Injection of RNA Nanoparticles Carrying both Ligand and siRNA.
Cui D; Zhang C; Liu B; Shu Y; Du T; Shu D; Wang K; Dai F; Liu Y; Li C; Pan F; Yang Y; Ni J; Li H; Brand-Saberi B; Guo P
Sci Rep; 2015 Jul; 5():10726. PubMed ID: 26137913
[TBL] [Abstract][Full Text] [Related]
9. Stable RNA nanoparticles as potential new generation drugs for cancer therapy.
Shu Y; Pi F; Sharma A; Rajabi M; Haque F; Shu D; Leggas M; Evers BM; Guo P
Adv Drug Deliv Rev; 2014 Feb; 66():74-89. PubMed ID: 24270010
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of chemically synthesized monomeric phi29 pRNA nanoparticles for systemic delivery.
Abdelmawla S; Guo S; Zhang L; Pulukuri SM; Patankar P; Conley P; Trebley J; Guo P; Li QX
Mol Ther; 2011 Jul; 19(7):1312-22. PubMed ID: 21468004
[TBL] [Abstract][Full Text] [Related]
11. Radiolabeled RNA Nanoparticles for Highly Specific Targeting and Efficient Tumor Accumulation with Favorable
Wang H; Guo P
Mol Pharm; 2021 Aug; 18(8):2924-2934. PubMed ID: 34212728
[TBL] [Abstract][Full Text] [Related]
12. Delivery and biodistribution of siRNA for cancer therapy: challenges and future prospects.
Seth S; Johns R; Templin MV
Ther Deliv; 2012 Feb; 3(2):245-61. PubMed ID: 22834200
[TBL] [Abstract][Full Text] [Related]
13. Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery.
Shi B; Abrams M
J Histochem Cytochem; 2013 Jun; 61(6):407-20. PubMed ID: 23504369
[TBL] [Abstract][Full Text] [Related]
14. Specific delivery of delta-5-desaturase siRNA via RNA nanoparticles supplemented with dihomo-γ-linolenic acid for colon cancer suppression.
Xu Y; Pang L; Wang H; Xu C; Shah H; Guo P; Shu D; Qian SY
Redox Biol; 2019 Feb; 21():101085. PubMed ID: 30584980
[TBL] [Abstract][Full Text] [Related]
15. Rolling circle transcription-based polymeric siRNA nanoparticles for tumor-targeted delivery.
Lee JH; Ku SH; Kim MJ; Lee SJ; Kim HC; Kim K; Kim SH; Kwon IC
J Control Release; 2017 Oct; 263():29-38. PubMed ID: 28373128
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of small noncoding RNA for glioblastoma.
Yoo JY; Yeh M; Kaur B; Lee TJ
Cancer Lett; 2021 Mar; 500():274-280. PubMed ID: 33176185
[TBL] [Abstract][Full Text] [Related]
17. Extrahepatic Targeting of Oligonucleotides with Receptor-Binding Non-Immunoglobulin Scaffold Proteins.
Winkler J
Nucleic Acid Ther; 2018 Jun; 28(3):137-145. PubMed ID: 29733239
[TBL] [Abstract][Full Text] [Related]
18. Functional assays for specific targeting and delivery of RNA nanoparticles to brain tumor.
Lee TJ; Haque F; Vieweger M; Yoo JY; Kaur B; Guo P; Croce CM
Methods Mol Biol; 2015; 1297():137-52. PubMed ID: 25896001
[TBL] [Abstract][Full Text] [Related]
19. PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy.
Xie Y; Qiao H; Su Z; Chen M; Ping Q; Sun M
Biomaterials; 2014 Sep; 35(27):7978-91. PubMed ID: 24939077
[TBL] [Abstract][Full Text] [Related]
20. RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21.
Lee TJ; Yoo JY; Shu D; Li H; Zhang J; Yu JG; Jaime-Ramirez AC; Acunzo M; Romano G; Cui R; Sun HL; Luo Z; Old M; Kaur B; Guo P; Croce CM
Mol Ther; 2017 Jul; 25(7):1544-1555. PubMed ID: 28109960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
